PerkinElmer Teams with Luminex to Develop Solutions for High Volume Disease Screening
PerkinElmer, Inc. (NYSE: PKI), a leading provider of drug discovery, life science research, and analytical solutions, and Luminex(R) Corporation (Nasdaq: LMNX), a leading multiplex solution developer, announced today a long-term licensing agreement to provide PerkinElmer access to Luminex’s xMAP(R) technology and assay development capabilities of the Luminex Bioscience Group.
Under the terms of the agreement, PerkinElmer will utilize Luminex’s xMAP technology in several areas of life science research and in vitro diagnostics. Focus areas are expected to include biomarker panels for pharmaceutical development and ADME/Tox as well as developing in vitro diagnostics in maternal, neonatal and prenatal health. PerkinElmer also plans to standardize its multiplex assay development on the Luminex xMAP platform.
Demand for multiplex testing, or performing multiple biomedical tests on a single sample, continues to accelerate for disease screening and discovery markets. To meet this need, PerkinElmer plans to offer the Luminex xMAP platform as part of its strategy to provide its customers leading products and solutions in the area of high volume disease screening.
“Providing our customers with access to a proven multiplexing solution is essential to assist their specific research and development needs and long-term growth,” said Peter Coggins, Ph.D., president of PerkinElmer Life and Analytical Sciences. “We have selected Luminex’s xMAP technology as a recognized industry benchmark in multiplexed life science research and diagnostics applications. We look forward to working closely and collaboratively to benefit our respective customers.”
Patrick Balthrop, Luminex’s president and chief executive officer, commented, “This agreement with PerkinElmer is a prime example of our company’s growing emphasis on establishing long-term partnerships with market leaders in segments of strategic significance to Luminex. In this relationship with PerkinElmer we are not only providing new markets and customers with access to the Luminex xMAP technology, we are also partnering with a premier company with significant market presence. We are excited to have PerkinElmer on board and look forward to pursuing additional collaborative opportunities with them in the future.”